|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM211910767 |
| 003 |
DE-627 |
| 005 |
20231224014523.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2011 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2011.08.009
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0706.xml
|
| 035 |
|
|
|a (DE-627)NLM211910767
|
| 035 |
|
|
|a (NLM)21964417
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Kiraly, Alex
|e verfasserin
|4 aut
|
| 245 |
1 |
2 |
|a A novel aza-anthrapyrazole blocks the progression of experimental autoimmune encephalomyelitis after the priming of autoimmunity
|
| 264 |
|
1 |
|c 2011
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 26.01.2012
|
| 500 |
|
|
|a Date Revised 21.11.2013
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2011 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Mitoxantrone is one of the few FDA-approved drugs available to treat rapidly progressing forms of multiple sclerosis; however, its utilization is compromised by a cardiotoxic potential and the risk of mitoxantrone-induced leukemia. BBR3378, a novel aza-anthrapyrazole, is structurally similar to mitoxantrone, but lacks the ring hydroxyls that may contribute to cardiotoxicity. Here, we investigated the therapeutic activity of BBR3378 in a C57BL/6 mouse model of multiple sclerosis. Mice given BBR3378, before or after the priming and expansion of MOG-specific responses, were protected from ascending paralysis. Strikingly, two doses of BBR3378 given a week after EAE induction were sufficient to provide significant protection from clinical symptoms and reduce MOG-specific proinflammatory T cell cytokine production, and serum IgG responses. Furthermore, while mitoxantrone is associated with persistent lymphopenia and cardiotoxicity, no such outcomes were detected in BBR3378-treated mice. Our findings show that BBR3378 can ameliorate encephalitogenic mechanisms in EAE and antagonize underlying autoimmune mechanisms
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a BBR3378
|2 NLM
|
| 650 |
|
7 |
|a Cytokines
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulin G
|2 NLM
|
| 650 |
|
7 |
|a Mog protein, mouse
|2 NLM
|
| 650 |
|
7 |
|a Myelin Proteins
|2 NLM
|
| 650 |
|
7 |
|a Myelin-Oligodendrocyte Glycoprotein
|2 NLM
|
| 650 |
|
7 |
|a Mitoxantrone
|2 NLM
|
| 650 |
|
7 |
|a BZ114NVM5P
|2 NLM
|
| 700 |
1 |
|
|a Koffman, Boyd
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hacker, Miles
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gunning, William
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Rasche, Sarah
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Quinn, Anthony
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 141(2011), 3 vom: 02. Dez., Seite 304-16
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:141
|g year:2011
|g number:3
|g day:02
|g month:12
|g pages:304-16
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2011.08.009
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 141
|j 2011
|e 3
|b 02
|c 12
|h 304-16
|